KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) EBIT: 2009-2024

Historic EBIT for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $4.0 billion.

  • Regeneron Pharmaceuticals' EBIT fell 12.95% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 billion, marking a year-over-year decrease of 7.18%. This contributed to the annual value of $4.0 billion for FY2024, which is 1.39% down from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its EBIT stood at $4.0 billion for FY2024, which was down 1.39% from $4.0 billion recorded in FY2023.
  • Regeneron Pharmaceuticals' 5-year EBIT high stood at $8.9 billion for FY2021, and its period low was $3.6 billion during FY2020.
  • In the last 3 years, Regeneron Pharmaceuticals' EBIT had a median value of $4.0 billion in 2023 and averaged $4.3 billion.
  • Per our database at Business Quant, Regeneron Pharmaceuticals' EBIT soared by 150.15% in 2021 and then tumbled by 47.03% in 2022.
  • Over the past 5 years, Regeneron Pharmaceuticals' EBIT (Yearly) stood at $3.6 billion in 2020, then surged by 150.15% to $8.9 billion in 2021, then crashed by 47.03% to $4.7 billion in 2022, then fell by 14.60% to $4.0 billion in 2023, then decreased by 1.39% to $4.0 billion in 2024.